Skip to main content
Premium Trial:

Request an Annual Quote

New Cancer Biomarker Company Formed in UK

NEW YORK (GenomeWeb News) – A new company called Oxford Cancer Biomarkers has been formed to provide oncology consulting services and new cancer biomarkers.

The company, which is headquartered in Oxford and Reading, UK, is developing new biomarkers using CancerNav, a DNA- and protein-based assay technology platform developed by Nick La Thangue, chair of cancer biology at Oxford University, and David Kerr, professor of cancer medicine at the university.

Quintiles is the largest shareholder in Oxford Cancer Biomarkers. La Thangue, Kerr, and the University of Oxford are the other major shareholders.

Oxford Cancer Biomarkers has a strategic relationship with Quintiles Consulting and Quintiles Global Laboratories, which Quintiles said has the "capabilities and expertise to operationalize the consulting and biomarker R&D innovations" from Oxford Cancer Biomarkers for use by global biopharm companies.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.